Search research articles
Contact Us
Filters
Showing results (21-30 of 47) with videos related to
Page
of 5
Sort By:
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
August 2, 2021
A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment
Edward Kerwin, Paul Dorinsky, Mehul Patel, et al.
Advances in Therapy
|
April 27, 2020
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β<sub>2</sub>-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
Gary T Ferguson, Patrick Darken, Shaila Ballal, et al.
Respiratory Medicine
|
June 3, 2018
Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial
Edward Kerwin, Andrew Wachtel, Lawrence Sher, et al.
Respiratory Medicine
|
May 5, 2018
Randomized study of the effects of Aerochamber Plus<sup>®</sup> Flow-Vu<sup>®</sup> on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease
Faisal Fakih, Selwyn Spangenthal, Barry Sigal, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 13, 2022
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Mona Bafadhel, Klaus F Rabe, Fernando J Martinez, et al.
ERJ Open Research
|
December 17, 2025
Short-acting β<sub>2</sub>-agonist use, exacerbation risk and triple therapy in COPD: <i>post hoc</i> analyses of ETHOS
John R Hurst, Dave Singh, Fernando J Martinez, et al.
BMC Pulmonary Medicine
|
July 17, 2014
Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease
Stephen Rennard, Charles Fogarty, Colin Reisner, et al.
Therapeutic Advances in Respiratory Disease
|
July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factors
Dave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Medicine
|
June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial
Fernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Thorax
|
June 14, 2020
Association between COPD exacerbations and lung function decline during maintenance therapy
Marjan Kerkhof, Jaco Voorham, Paul Dorinsky, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 47) with videos related to
Sort By:
Page
of 5
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
August 2, 2021
A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment
Edward Kerwin, Paul Dorinsky, Mehul Patel, et al.
Advances in Therapy
|
April 27, 2020
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β<sub>2</sub>-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
Gary T Ferguson, Patrick Darken, Shaila Ballal, et al.
Respiratory Medicine
|
June 3, 2018
Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial
Edward Kerwin, Andrew Wachtel, Lawrence Sher, et al.
Respiratory Medicine
|
May 5, 2018
Randomized study of the effects of Aerochamber Plus<sup>®</sup> Flow-Vu<sup>®</sup> on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease
Faisal Fakih, Selwyn Spangenthal, Barry Sigal, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 13, 2022
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Mona Bafadhel, Klaus F Rabe, Fernando J Martinez, et al.
ERJ Open Research
|
December 17, 2025
Short-acting β<sub>2</sub>-agonist use, exacerbation risk and triple therapy in COPD: <i>post hoc</i> analyses of ETHOS
John R Hurst, Dave Singh, Fernando J Martinez, et al.
BMC Pulmonary Medicine
|
July 17, 2014
Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease
Stephen Rennard, Charles Fogarty, Colin Reisner, et al.
Therapeutic Advances in Respiratory Disease
|
July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factors
Dave Singh, John R Hurst, Fernando J Martinez, et al.
Respiratory Medicine
|
June 25, 2021
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial
Fernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
Thorax
|
June 14, 2020
Association between COPD exacerbations and lung function decline during maintenance therapy
Marjan Kerkhof, Jaco Voorham, Paul Dorinsky, et al.
Page
of 5